{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:50:02Z","timestamp":1775749802444,"version":"3.50.1"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec id=\"ab-ooi250101-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Immunotherapy is approved for first-line treatment of recurrent\/metastatic head and neck cancer (HNC). The prescribing patterns are largely unreported, and assessment of immune-related adverse events (irAEs) in patients with HNC is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi250101-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the prescribing patterns of immunotherapy and the incidence and risk factors for irAEs using a claims-based database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi250101-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study of MarketScan Commercial and multistate Medicaid databases of all patients with HNC from January 1, 2016, to December 31, 2022, was performed. Inclusion criteria were patients with HNC, defined by\n                      <jats:italic toggle=\"yes\">International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)<\/jats:italic>\n                      codes with 6 months or longer of insurance enrollment prior to diagnosis and 1 or more months of follow-up. The databases excluded patients 65 years or older. Statistical analysis was conducted from October 1, 2024, through December 31, 2024.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi250101-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Prescription of an immunotherapeutic within 12 months after HNC diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi250101-8\">\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>The primary outcome measure was prescribing rate of immunotherapeutics overall and per year. The relative use of each immunotherapeutic was also explored. Secondary outcome measures were incidence of irAEs, severe irAEs, and univariable\/multivariate risk factors for irAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi250101-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 47\u202f365 patients with HNC were included, and 2254 (4.8%) of these patients received immunotherapy. Overall, 32\u202f195 participants were male individuals (68%) and 14\u202f607 were female individuals (32%), with a mean (SD) age of 54 (9) years. The rate of immunotherapy prescriptions slightly increased over time from 2.3% of patients with HNC in 2017 to 2.8% in 2022 (percent change, 0.5%; 95% CI, 0.1%-0.9%). Following initial approval by the US Food and Drug Administration (FDA), prescribing patterns of pembrolizumab and nivolumab were similar, but divergence in 2019 led to 87% of the market share dominated by pembrolizumab by 2022. The 90-day overall irAE-rate was 41.2% and severe irAE rate was 2.7%. There was no association between medication use and irAEs. Comorbidity score was associated with severe irAEs at 90 days (odds ratio [OR], 1.02; 95% CI, 1.02-1.03). Baseline hypothyroidism (adjusted OR [aOR], 6.7; 95% CI, 5.0-9.0) and liver disease (aOR, 1.7; 95% CI, 1.1-2.7) were independently associated with the development of irAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi250101-10\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This cohort study found that pembrolizumab dominated the immunotherapy prescribing market, but the relative use of immunotherapy has minimally increased in patients younger than 65 years since FDA approval. irAEs were frequent and associated with key individual comorbidities. Severe irAEs were rare and associated with overall comorbidity status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoto.2025.5513","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:00:16Z","timestamp":1771516816000},"page":"384","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Patients With Head and Neck Cancer"],"prefix":"10.1001","volume":"152","author":[{"given":"Andrew M.","family":"Peterson","sequence":"first","affiliation":[{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Stwalley","sequence":"additional","affiliation":[{"name":"Institute for Informatics, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorina","family":"Kallogjeri","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"},{"name":"Statistics Editor, JAMA Otolaryngology\u2013Head & Neck Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex R.","family":"Harbison","sequence":"additional","affiliation":[{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrik","family":"Pipkorn","sequence":"additional","affiliation":[{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan S.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidharth V.","family":"Puram","sequence":"additional","affiliation":[{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay F.","family":"Piccirillo","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"},{"name":"Editor in Chief, JAMA Otolaryngology\u2013Head & Neck Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Zolkind","sequence":"additional","affiliation":[{"name":"Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"6","key":"ooi250101r1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"ooi250101r2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10212","key":"ooi250101r3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"ooi250101r4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"ooi250101r5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","article-title":"Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis.","volume":"147","author":"Masarwy","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"19","key":"ooi250101r6","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial.","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ooi250101r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100426","article-title":"Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.","volume":"2","author":"Knochelmann","year":"2021","journal-title":"Cell Rep Med"},{"issue":"10","key":"ooi250101r8","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1158\/1078-0432.CCR-23-3249","article-title":"A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.","volume":"30","author":"Kim","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ooi250101r9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial.","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"ooi250101r10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"ooi250101r11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer.","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"ooi250101r12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol"},{"key":"ooi250101r13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry.","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"},{"issue":"16-17","key":"ooi250101r14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/1750743X.2024.2409617","article-title":"Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma.","volume":"16","author":"Elghawy","year":"2024","journal-title":"Immunotherapy"},{"issue":"24","key":"ooi250101r15","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"ooi250101r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival among veterans receiving steroids for immune-related adverse events after immune checkpoint inhibitor therapy.","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"ooi250101r17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"issue":"11","key":"ooi250101r18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"5","key":"ooi250101r19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/pds.5204","article-title":"Validation of an International Classification of Disease, 10th revision coding adaptation for the Charlson Comorbidity Index in United States healthcare claims data.","volume":"30","author":"Beyrer","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"ooi250101r20","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors.","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"ooi250101r21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study.","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"ooi250101r22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients.","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"ooi250101r23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s40425-019-0714-x","article-title":"Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"10167","key":"ooi250101r24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"ooi250101r25","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jamaoto.2023.2420","article-title":"Differences in receipt of immunotherapy treatment among patients with head and neck cancer.","volume":"149","author":"Ramkumar","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ooi250101r26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.14639\/0392-100X-suppl.1-40-2020","article-title":"Metastatic disease in head & neck oncology.","volume":"40","author":"Pisani","year":"2020","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"11","key":"ooi250101r27","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations.","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"ooi250101r28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s40425-019-0782-y","article-title":"Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma.","volume":"7","author":"Krimphove","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"16","key":"ooi250101r29","doi-asserted-by":"publisher","first-page":"12061","DOI":"10.1200\/JCO.2023.41.16_suppl.12061","article-title":"Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy.","volume":"41","author":"Faucheux","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"ooi250101r30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2217\/imt-2023-0270","article-title":"Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events.","volume":"16","author":"Onur","year":"2024","journal-title":"Immunotherapy"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2845402\/jamaotolaryngology_peterson_2026_oi_250101_1775660462.40698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:00:33Z","timestamp":1775746833000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2845402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2025.5513","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}